Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of Vaccine Against Coronavirus

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that the first participant has been dosed in the Phase 1 study of the Company’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2). This Phase 1 study is being conducted by the US National Institutes of Health (NIH) under its own Investigational New Drug (IND) application.

Photo by Martin Sanchez on Unsplash

Tags:

COVID-19

Nicole Verbeeck

Nicole Verbeeck is Founder and Editor-in-Chief of Moonshot for Life, covering global health progress. She is also founder of Juneau Cayenne, a creative design, content and technology lab crafting innovative storytelling experiences for clients in healthcare and life sciences worldwide and she is a healthy food chef focusing on prevention of disease.